Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and...

FDA Recall #D-0264-2022 — Class III — November 19, 2021

Recall #D-0264-2022 Date: November 19, 2021 Classification: Class III Status: Terminated

Product Description

Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13.

Reason for Recall

Subpotent Drug

Recalling Firm

Lupin Pharmaceuticals Inc. — Baltimore, MD

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

4113 cartons

Distribution

nationwide within the United States

Code Information

Lot #: L000784 and L000785, Exp. Date May 2022

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated